Pharmaceuticals have done well in China over the long-term for many years. Given the quality of JiangSu HengRui and its perpetual growth, there is no reason why this trend should abate over the long haul. This stock is immune to a trade war, yet not immune to business cycle risks, which has caused turbulence for weeks to months before.
I am a little late to publish this article, but it follows up on a previous article that I wrote and posted regarding China's Roaring 2020s.
I am a little late to publish this article, but it follows up on a previous article that I wrote and posted regarding China's Roaring 2020s.
注释
Just more opportunity to buy at a favorable price:注释
交易结束：到达目标
注释
交易结束：到达目标
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。